Ad is loading...
DFSVX vs QRSIX
DFSVX vs QRSIX Comparison
Open Charts DFSVX vs QRSIX
DFA US Small Cap Value I
Price$42.14
Change+$0.81 (+1.96%)
VolumeN/A
Net Assets13.89B
FPA Queens Road Small Cap Value Instl
Price$37.10
Change+$0.79 (+2.18%)
VolumeN/A
Net Assets789.45M
DFSVX vs QRSIX Comparison Chart
Loading...
View a ticker or compare two or three
VS
VS
FUNDAMENTALS
Fundamentals
DFSVX has more cash in the bank: 13.9B vs. QRSIX (789M). DFSVX pays higher dividends than QRSIX: DFSVX (1.65) vs QRSIX (0.95). DFSVX was incepted earlier than QRSIX: DFSVX (32 years) vs QRSIX (4 years). QRSIX (0.79) is less costly to investors than DFSVX (0.31). QRSIX is a more actively managed with annual turnover of: 13.00 vs. DFSVX (12.00). DFSVX has a lower initial minimum investment than QRSIX: DFSVX (0) vs QRSIX (100000). QRSIX annual gain was more profitable for investors over the last year : -0.36 vs. DFSVX (-8.03).
| DFSVX | QRSIX | DFSVX / QRSIX | |
| Total Expense Ratio | 0.31 | 0.79 | 39% |
| Annual Report Gross Expense Ratio | 0.31 | 0.79 | 39% |
| Fund Existence | 32 years | 4 years | - |
| Gain YTD | -15.444 | -6.802 | 227% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 100000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 13.9B | 789M | 1,762% |
| Annual Yield % from dividends | 1.65 | 0.95 | 173% |
| Returns for 1 year | -8.03 | -0.36 | 2,228% |
| Returns for 3 years | 0.80 | 9.17 | 9% |
| Returns for 5 years | 95.08 | N/A | - |
| Returns for 10 years | 19.34 | N/A | - |
View a ticker or compare two or three
VS
VS
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RICBX | 54.36 | 1.21 | +2.28% |
| American Funds Invmt Co of Amer R2 | |||
| FSAEX | 11.16 | N/A | N/A |
| Fidelity Series All-Sector Equity | |||
| ADRRX | 17.08 | N/A | N/A |
| American Century Disciplined Growth R | |||
| PZINX | 10.98 | N/A | N/A |
| Pzena International Value Instl | |||
| ETAHX | 29.33 | N/A | N/A |
| Eventide Healthcare & Life Sciences A | |||